Perpetual Ltd Invests $201,000 in Becton, Dickinson and Company (NYSE:BDX)

June 30, 2025

[ad_1]

Perpetual Ltd bought a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 879 shares of the medical instruments supplier’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Hillsdale Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after purchasing an additional 50 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 53 shares in the last quarter. Brady Family Wealth LLC lifted its stake in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after buying an additional 53 shares in the last quarter. Picton Mahoney Asset Management lifted its stake in shares of Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares in the last quarter. Finally, REAP Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the business’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Shan sold 1,166 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.

Analysts Set New Price Targets

Want More Great Investing Ideas?

A number of research firms have recently weighed in on BDX. Stifel Nicolaus dropped their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a research note on Tuesday, May 6th. Bank of America cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price on the stock. in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $219.22.

Read Our Latest Research Report on BDX

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $170.83 on Monday. The company’s 50 day moving average is $176.53 and its 200-day moving average is $209.30. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm has a market cap of $48.96 billion, a P/E ratio of 32.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.17 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.